Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGDS | O60760 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | FBP1 | P09467 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.31 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30423529 | 1.00 | TSHR (0.40) | TSHRLMNANOS1CYP1A2ALDH1A1 | |
| SCHEMBL7073829 | 0.88 | — | — | |
| SCHEMBL29054 | 0.88 | — | — | |
| SCHEMBL3276946 | 0.85 | — | — | |
| Hydrogen Sulfide SCHEMBL29248841 | 0.85 | — | — | |
| SCHEMBL497681 | 0.85 | — | — | |
| SCHEMBL6830319 | 0.85 | — | — | |
| SCHEMBL2975655 | 0.85 | — | — | |
| Ammonia Solution, Strong SCHEMBL28811677 | 0.85 | — | — | |
| SCHEMBL8666743 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3062458-A | — | — | None | — | — | JP | disclosed |
| EP-3593786-B1 | PHOTOCURABLE COMPOSITION AND DENTAL RESTORATION FILLING MATERIAL | TOKUYAMA DENTAL CORP (JP) | 2022-05-18 | — | — | EP | disclosed |
| US-11273104-B2 | Photocurable composition and dental restoration filling material | TOKUYAMA DENTAL CORPORATION (JP) | 2022-03-15 | — | — | US | disclosed |
| EP-3427716-B1 | PHOTOPOLYMERIZATION INITIATOR AND PHOTOCURABLE COMPOSITION | TOKUYAMA DENTAL CORP (JP) | 2021-11-24 | — | — | EP | disclosed |
| CN-108697586-B | Photopolymerization initiator and photocurable composition | 株式会社德山齿科 | 2021-07-06 | — | — | CN | disclosed |
| US-20210095055-A1 | PHOTOPOLYMERIZATION INITIATOR AND PHOTOCURABLE COMPOSITION | TOKUYAMA DENTAL CORPORATION (JP) | 2021-04-01 | — | — | US | disclosed |
| US-20200069534-A1 | PHOTOCURABLE COMPOSITION AND DENTAL RESTORATION FILLING MATERIAL | TOKUYAMA DENTAL CORPORATION (JP) | 2020-03-05 | — | — | US | disclosed |
| CN-110249007-A | Thiosulfonic acid is synthesized with the oxidative coupling step that the periodic acid class of aniline mediates by thiosulfonic acid | 维斯塔实验室有限公司 | 2019-09-17 | — | — | CN | disclosed |
| CN-110092764-A | Diaminophenothiazine compound includes the chemical synthesis process of methyl sulfonium chloride (MTC) | 维斯塔实验室有限公司 | 2019-08-06 | — | — | CN | disclosed |
| CN-109789148-A | Administration and dosage of diaminophenothiazines | 维斯塔实验室有限公司 | 2019-05-21 | — | — | CN | disclosed |
| US-20050245652-A1 | Compositions for use in golf balls | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT | 2005-11-03 | — | — | US | disclosed |
| US-20050245657-A1 | Compositions for use in golf balls | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT | 2005-11-03 | — | — | US | disclosed |
| EP-0738928-B1 | Visible-ray polymerization initiator and visible-ray polymerizable composition | TOKUYAMA CORP (JP) | 2001-06-20 | — | — | EP | disclosed |
| WO-1999066307-A1 | APPARATUS AND METHODS FOR DETERMINING THE TIME OF DEATH OF AN ORGANISM | BIOMAX TECHNOLOGIES, INC. (CA) | 1999-12-23 | — | — | WO | disclosed |
| WO-1998052017-A1 | APPARATUS AND METHODS FOR DETERMINING THE TIME OF DEATH OF AN ORGANISM | BIOMAX TECHNOLOGIES, INC. (CA) | 1998-11-19 | — | — | WO | disclosed |
| US-5744511-A | BLEND OF COUMARIN DYES, ACID GENERATOR AND ARYL BORATE | TOKUYAMA CORPORATION (JP) | 1998-04-28 | — | — | US | disclosed |
| EP-0738928-A2 | Visible-ray polymerization initiator and visible-ray polymerizable composition | TOKUYAMA CORPORATION (JP) | 1996-10-23 | — | — | EP | disclosed |
| US-5500760-A | Electrochemichromic solutions, processes for preparing and using the same, and devices manufactured with the same | DONNELLY CORPORATION (US) | 1996-03-19 | — | — | US | disclosed |
| EP-0531143-A2 | Electrochemichromic solutions, processes for preparing and using the same, and devices manufactured with the same | DONNELLY CORPORATION (US) | 1993-03-10 | — | — | EP | disclosed |
| JP-H0362458-A | LITHIUM BATTERY | MITSUBISHI ELECTRIC CORP | 1991-03-18 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11273104-B2 | Photocurable composition and dental restoration filling material | H1-0, REV1, RER1 | TSHR 3666/4885LMNA 266/4885NOS1 31/4885 |
| US-20210095055-A1 | PHOTOPOLYMERIZATION INITIATOR AND PHOTOCURABLE COMPOSITION | INO80C, JAK2, PCNA | TSHR 1296/4885LMNA 1349/4885NOS1 1946/4885 |
| US-20200069534-A1 | PHOTOCURABLE COMPOSITION AND DENTAL RESTORATION FILLING MATERIAL | REV1, H1-0, RAD51 | TSHR 3713/4885LMNA 271/4885NOS1 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.